Zelnorm returns
Executive Summary
Novartis drug will be available under a treatment investigational new drug protocol to treat irritable bowel syndrome with constipation and chronic idiopathic constipation in women under 55, FDA announces July 27. Marketing of tegaserod maleate was suspended in March after a pooled data analysis of 29 clinical trials revealed a higher chance of heart attack, stroke and worsening heart chest pain in patients treated with Zelnorm compared to those on placebo (1"The Pink Sheet" April 2, 2007, p. 3)...
You may also be interested in...
Door Open For Zelnorm Return Despite Marketing “Suspension,” Novartis Says
Novartis is emphasizing that the removal of Zelnorm from the market is a suspension rather than a withdrawal
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.